Contact Us
THANK YOU FOR VISITING ABBOTT BOOTH AND WE HOPE THAT YOU ENJOYED THE INFORMATION SHARED.
If you have any unanswered questions or would like to know more about Abbott or our products, please fill in the following form and we will get back to you shortly.
Abbott is committed to protecting and respecting your privacy. We only use your personal information to provide the information you have requested from us. In order to provide you with the information requested, we need to store and process your personal data. If you consent to us storing your personal data for this purpose, please tick the checkbox below.
Scientific Literatures
Dydrogesterone is a selective progesterone receptor agonist with high oral bioavailability. These key pharmacokinetic features allow for effective oral administration and may limit the risk of side-effects. Clinical studies have shown that oral dydrogesterone has a good benefit–risk profile, comparable to that of micronized vaginal progesterone, during luteal phase support.
A Phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization
Oral dydrogesterone may replace MVP as the standard of care for luteal phase support in IVF, owing to the oral route being more patient-friendly than intravaginal administration, as well as it being a well-tolerated and efficacious treatment.
Oral dydrogesterone versus intravaginal micronized progesterone gel for luteal phase support in IVF: a randomized clinical trial
Oral dydrogesterone is well tolerated and has a similar safety profile to MVP gel. Non-inferiority of oral dydrogesterone was demonstrated, with comparable pregnancy rates and live birth rates in the oral dydrogesterone and MVP gel groups.
Clinical Summaries
Authors: Griesinger G, Blockeel C, and Tournaye H
Publication: Fertility and Sterility Vol. 109, No. 5, May 2018
A Phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization
Authors: Tournaye H, Sukhikh G, Kahler E, and Griesinger G
Publication: Human Reproduction, Vol.32, No.5 pp. 1019–1027, 2017
Oral dydrogesterone versus intravaginal micronized progesterone gel for luteal phase support in IVF: a randomized clinical trial
Authors: Griesinger G, Blockeel C, Sukhikh GT, Patki A, Dhorepatil B, Yang DZ, Chen ZJ, Kahler E, Pexman-Fieth C, and Tournaye H
Publication: Human Reproduction, Vol.33, No.12 pp. 2212–2221, 2018
Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double-blind, randomized, parallel, placebo-controlled trial
Authors: Kumar A, Begum N, Prasad S, Aggarwal S, and Sharma S
Publication: Fertility and Sterility Vol. 102, No. 5, November 2014
Modulating fertility outcome in assisted reproductive technologies by the use of dydrogesterone
Authors: Patki A, and Pawar VC
Publication: Gynecological Endocrinology, 2007; 23(S1): 68–72